Novo Nordisk A/S

GlaxoSmithKline (GSK) reported a 19.0% rise in 1Q17 revenues to ~7.4 billion pounds, driven by an operational rise of 5.0% and a favorable currency impact of 14.0%.

A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.

Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.

Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.

Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.

Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues.

On February 16, 2017, Sanofi was trading at a forward PE multiple of ~13.9x, as compared to the industry average of 15.7x.

During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner.

Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients.

During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner.

A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock.

Novo Nordisk’s search for new molecules through partnerships and other alliances has proven instrumental in strengthening its R&D pipeline.

In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.

Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.

Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.

LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug.

BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million.

Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16.

As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market.

The Scandinavian indexes were trading on a higher note towards the end of the day on July 11 following higher inflation numbers in Scandinavian countries.

Novartis’s new structure includes only three business segments: pharmaceuticals, Alcon, and Sandoz.

Novo Nordisk’s US sales rose annually by 12% in local currency in 1Q16. North America remained its major market, constituting ~50% of its total revenue.

Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology.

Novo Nordisk’s research and development pipeline includes three late-stage insulin studies of faster-acting insulin aspart, semaglutide, and LATIN T1D.

Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically.

Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.

Novo Nordisk’s (NVO) business model includes a portfolio in areas such as diabetes, hemophilia, and growth hormones. In the first half of 2015, diabetes care accounted for 78.6% of its total revenues.

Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world.